DiaMedica Therapeutics Inc. has announced the successful closing of a $30.1 million private placement of common shares to accredited investors. The clinical-stage biopharmaceutical company, which is focused on developing novel treatments for conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke, sold approximately 8.6 million common shares at a price of $3.50 per share. After deducting estimated offering expenses, DiaMedica received net proceeds of approximately $29.9 million. With these proceeds, the company's cash, cash equivalents, and short-term investments would have been $67.2 million as of March 31, 2025, on a pro forma basis. DiaMedica has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale of the common shares issued in this private placement.